Dr. Vincent Fradet (MD, PhD, FRCSC) is an uro-oncologist with a focused clinical practice at CHU de Québec-Laval University. He completed his medical training at Université de Montréal with an MD and residency in urology. He pursued with 5 years of subspecialty and research training. He obtained his uro-oncology accreditation from the Society of Urologic Oncology at the University of California, in San Francisco (UCSF) and completed a PhD in Clinical Research/Epidemiolgy (University de Montréal). Dr. Fradet has been an Associate Professor at Laval University since 2009, and is a regular researcher at the Laval University Cancer Research Center and at INAF (Institute for Nutrition and functional Food).

Dr. Fradet’s research goal is to improve our understanding of the links between lifestyle factors, including dietary omega-3 fatty acids and exercise, quality of life parameters, inflammation, and oncogenic pathways in prostate cancer, to progressively develop personalized preventive and treatment strategies. To that end, Dr. Fradet has built a unique biobank of bio-samples, developed pre-clinical models (mouse and primary cells in culture) and is running some clinical studies. All the epidemiological, clinical, and molecular (translational) projects led by his team are focused on improving our understanding of the biological mechanisms and the impact on quality of life of prostate cancer, as well as on developing biomarkers (urinary, blood, epigenetics, molecular and/or cellular) to be used in future intervention studies to stratify or select and monitor patients.

L'Hôtel-Dieu de Québec
6, rue McMahon
0622
Québec, Québec
Canada G1R 2J6
+1 418-525-4444, extension 15568 ou 20414 ou 16848
Vincent.Fradet@crchudeque... vincent.fradet@fmed.ulava...

Latest news

41 entries « ‹ 1 of 5 › »

Lamarre M, Tremblay T, Bansept MA, Robitaille K, Fradet V, Giguère D, Boudreau D

A glycan-based plasmonic sensor for prostate cancer diagnosis.

Journal Article

Analyst, 2021.

Abstract | Links:

Otis-Chapados S, Goulet CR, Dubois G, Lavallee E, Dujardin T, Fradet Y, Lacombe L, Lodde M, Tiguert R, Toren P, Fradet V, Beauregard JM, Buteau FA, Pouliot F

F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy.

Journal Article

Can Urol Assoc J, 2021.

Abstract | Links:

Fervaha G, Izard JP, Tripp DA, Aghel N, Shayegan B, Klotz L, Niazi T, Fradet V, Taussky D, Lavallee LT, Hamilton RJ, Brown I, Chin J, Gopaul D, Violette PD, Davis MK, Karampatos S, Pinthus JH, Leong DP, Siemens DR

Psychological morbidity associated with prostate cancer: Rates and predictors of depression in the RADICAL PC study.

Journal Article

Can Urol Assoc J, 15 (6), 2021.

Abstract | Links:

Gevariya N, Lachance G, Robitaille K, Joly Beauparlant C, Beaudoin L, Fournier E, Fradet Y, Droit A, Julien P, Marette A, Bergeron A, Fradet V

Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity.

Journal Article

Mol Cancer Res, 19 (3), 2021.

Abstract | Links:

Bilodeau JF, Gevariya N, Larose J, Robitaille K, Roy J, Oger C, Galano JM, Bergeron A, Durand T, Fradet Y, Julien P, Fradet V

Long chain omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth.

Journal Article

Prostaglandins Leukot Essent Fatty Acids, 164 , 2021.

Abstract | Links:

Loubersac T, Nguile-Makao M, Pouliot F, Fradet V, Toren P

Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study.

Journal Article

Eur Urol Oncol, 3 (3), 2020.

Abstract | Links:

Koti M, Berman DM, Siemens DR, Lange D, Wang E, Toren P, Eigl BJ, Hardy C, Purves R, Fradet V, Fradet Y, Mansure J, Kassouf W, Black PC

Building a Canadian Translational Bladder Cancer Research Network.

Journal Article

Can Urol Assoc J, 14 (10), 2020.

| Links:

Gotto G, Drachenberg DE, Chin J, Casey R, Fradet V, Sabbagh R, Shayegan B, Rendon RA, Danielson B, Camacho F, Zardan A, Plante R, Hew H, Chan K, Feifer A

Real-world evidence in patient-reported outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate + prednisone (AA+P) across Canada: Final results of COSMiC.

Journal Article

Can Urol Assoc J, 14 (12), 2020.

Abstract | Links:

Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, Klotz L, Brown I, Chin J, Lavallee L, Mousavi N, Luke P, Lukka H, Gopaul D, Violette P, Hamilton RJ, Davis MK, Karampatos S, Mian R, Delouya G, Fradet Y, Mukherjee S, Conen D, Chen-Tournoux A, Johnson C, Bessissow A, Dresser G, Hameed AK, Abdel-Qadir H, Sener A, Pal R, Devereaux PJ, Pinthus J

Cardiovascular Risk in Men with Prostate Cancer: Insights from the RADICAL PC Study.

Journal Article

J Urol, 203 (6), 2020.

Abstract | Links:

Nguile-Makao M, Allard MA, Bairati I, Meyer F, Robitaille K, Fradet Y, Lacombe L, Pouliot F, Toren P, Duchesne T, Fradet V

Charlson Comorbidity Index as a Predictor of Cancer Mortality Beyond 10 Years after Radical Prostatectomy

Journal Article

Clin Oncol (Belmont), 4 , 2019.

41 entries « ‹ 1 of 5 › »
Signaler des ajouts ou des modifications

Active projects

  • En route towards prebiotic clinical trials for enhancement of immunotherapies in bladder and prostate cancers, from 2020-06-01 to 2023-05-31
  • Impact of lifestyle on gut barrier function, bacterial translocation and risk of prostate cancer, from 2020-09-01 to 2022-08-31
  • Institut sur la nutrition et les aliments fonctionnels (INAF), from 2017-04-01 to 2024-03-31
  • Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions., from 2012-10-01 to 2021-12-31
  • Les habitudes de vie en cancer de la prostate au coeur d’une médecine personnalisée, from 2021-07-01 to 2024-06-30

Recently finished projects

  • (FRSQ 85605) Plateforme méthodologique du CRCEO (statistiques uro-oncologie) , from 2019-05-30 to 2020-05-29
  • Détresse et satisfactions face au processus informationnel et décisionnel lors d'un cancer de la prostate localisé, from 2017-02-01 to 2020-03-31
  • Impact of microbiota on prostate cancer: from gut to tumor microenvironment., from 2018-12-01 to 2019-12-31
  • Plateforme méthodologique du Centre de Recherche Clinique et Evaluative en Oncoloie (CRCEO) uro-oncologie, from 2019-03-05 to 2020-03-04
  • Prebiotics to enhance immunotherapy response in bladder cancer, from 2019-01-01 to 2021-07-31
  • Projet de recherche CaptoMD : Cancer de la prostate, from 2019-03-22 to 2020-03-21
  • Territorialiser les systèmes alimentaires : une révolution pour la planète et la santé durable, from 2020-04-01 to 2021-03-31
  • Toward nutritional and epigenomic interventions in prostate cancer prevention and management, from 2017-10-01 to 2020-09-30
Data provided by the Université Laval research projects registery